Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29595776 | 1.00 | KISS1R (0.62) | KISS1R | |
| SCHEMBL30802584 | 0.97 | KISS1R (0.63) | KISS1R | |
| SCHEMBL30675548 | 0.95 | KISS1R (0.64) | KISS1R | |
| SCHEMBL30450426 | 0.94 | KISS1R (0.63) | KISS1R | |
| SCHEMBL23346292 | 0.94 | KISS1R (0.57) | KISS1R | |
| SCHEMBL23839903 | 0.93 | KISS1R (0.59) | KISS1R | |
| SCHEMBL18082492 | 0.92 | KISS1R (0.56) | KISS1R | |
| SCHEMBL19842025 | 0.91 | KISS1R (0.60) | KISS1R | |
| SCHEMBL20376152 | 0.91 | KISS1R (0.60) | KISS1R | |
| SCHEMBL20376297 | 0.91 | KISS1R (0.60) | KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3999094-B1 | A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE | RIGSHOSPITALET (DK) | 2026-02-25 | — | — | EP | disclosed |
| US-12409240-B2 | Positron emitting radionuclide labeled peptides for human uPAR PET imaging | CURASIGHT A/S (DK) | 2025-09-09 | — | — | US | disclosed |
| CN-114555623-B | Urokinase plasminogen activator receptor targeting peptides | 丹麦国家医院 | 2024-10-25 | — | — | CN | disclosed |
| US-20240066142-A1 | A UPAR (UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR)-TARGETING CONJUGATE | FLUOGUIDE A/S (DK) | 2024-02-29 | — | — | US | disclosed |
| EP-3590542-B1 | POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING | CURASIGHT AS (DK) | 2024-01-03 | — | — | EP | disclosed |
| US-20220401585-A1 | A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE | RIGSHOSPITALET (DK) | 2022-12-22 | — | — | US | disclosed |
| US-20220202966-A1 | POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING | CURASIGHT A/S (DK) | 2022-06-30 | — | — | US | disclosed |
| CN-114555623-A | Urokinase plasminogen activator receptor targeting peptides | 丹麦国家医院 | 2022-05-27 | — | — | CN | disclosed |
| EP-3999094-A1 | A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE | Rigshospitalet (DK) | 2022-05-25 | — | — | EP | disclosed |
| US-11311637-B2 | Positron emitting radionuclide labeled peptides for human uPAR PET imaging | CURASIGHT A/S (DK) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202966-A1 | POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING | PLAUR, PLAU, SERPINE1 | KISS1R 552/4885 |
| US-12409240-B2 | Positron emitting radionuclide labeled peptides for human uPAR PET imaging | PLAUR, PLAU, SERPINE1 | KISS1R 552/4885 |
| US-11311637-B2 | Positron emitting radionuclide labeled peptides for human uPAR PET imaging | PLAUR, PLAU, SERPINE1 | KISS1R 552/4885 |
| US-20220401585-A1 | A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE | PLAUR, PLAU, PLG | KISS1R 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.